Auvelity is used for the treatment of major depressive disorder (MDD) in adults [1][2]. It is a combination medication that contains the active ingredients dextromethorphan and bupropion [1].
How does Auvelity work?
Auvelity works by targeting two key neurotransmitter systems in the brain involved in mood regulation. Dextromethorphan is a NMDA receptor antagonist and a sigma-1 receptor agonist. Bupropion is an aminoketone antidepressant that acts as a norepinephrine and dopamine reuptake inhibitor. By combining these mechanisms, Auvelity aims to address the complexities of MDD [1].
What is the difference between Auvelity and other depression medications?
Auvelity distinguishes itself from many other antidepressants due to its dual mechanism of action, combining an NMDA receptor antagonist and a norepinephrine-dopamine reuptake inhibitor. Many standard antidepressants primarily focus on single neurotransmitter systems, such as serotonin or norepinephrine. This unique approach may offer a different therapeutic pathway for individuals with MDD [1].
When does Auvelity's patent expire?
The patent landscape for Auvelity is complex and involves patents covering the drug itself, its formulations, and methods of use. Information on specific patent expiry dates for Auvelity can be found on DrugPatentWatch.com [3].
Can generic versions of Auvelity be made before patents expire?
Generally, generic versions of a medication cannot be manufactured or marketed until the relevant patents have expired or have been successfully challenged and invalidated. The exclusivity period is designed to allow the innovator company to recoup research and development costs.
Who makes Auvelity?
Auvelity is developed and marketed by Axsome Therapeutics [1].
What are the side effects of Auvelity?
Common side effects reported with Auvelity include dizziness, headache, diarrhea, insomnia, and nausea [2]. Serious side effects can include suicidal thoughts and behaviors, as well as potential risks associated with bupropion, such as increased blood pressure and seizures [2].
What is the clinical data supporting Auvelity's use?
Clinical trials have demonstrated that Auvelity is effective in reducing depressive symptoms in adults with MDD. Studies have shown statistically significant improvements in depression rating scales compared to placebo [1].
What are the risks associated with taking Auvelity?
Patients taking Auvelity should be aware of potential risks, including the possibility of increased suicidal thoughts and behaviors, especially at the beginning of treatment or when the dose is changed. Bupropion, one of the active ingredients, also carries a risk of seizures, particularly at higher doses or in individuals with predisposing factors [2]. It is crucial for patients to discuss their full medical history and any potential risks with their healthcare provider.
Where can I find more information about Auvelity?
More detailed information regarding Auvelity, including its usage, clinical studies, and patent information, can be found on resources like DrugPatentWatch.com [3].
---
Sources:
[1] Auvelity (dextromethorphan-bupropion) tablets prescribing information. Axsome Therapeutics, Inc.
[2] Auvelity: Uses, side effects, dosage, warnings. Drugs.com.
[3] DrugPatentWatch.com